文献速递白血病造血干细胞移植与细胞治疗

地西他滨与伏立诺他联合FLAG方案治疗儿童复发/难治性急性髓系白血病:来自儿童白血病和淋巴瘤治疗进展(TACL)联盟的报告

Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
PubMed 文献 · Am J Hematol · 2022-03-08

该1期试验含剂量扩展队列,评估地西他滨与伏立诺他联合氟达拉滨、阿糖胞苷和G-CSF(FLAG)方案治疗儿童复发/难治性急性髓系白血病(R/R AML)的安全性和疗效。37例患者入组,未观察到剂量限制性毒性,推荐的2期剂量为地西他滨10 mg/m2。35例可评估患者总缓解率为54%,缓解者中90%达到微小残留病(MRD)阴性,2年总生存率MRD阴性组为75.6%,残留病组为17.9%(p < .001)。

要点

  • 地西他滨联合伏立诺他及FLAG方案在儿童R/R AML中未观察到剂量限制性毒性,推荐2期剂量为地西他滨10 mg/m2。
  • 35例可评估患者总缓解率为54%,其中16例完全缓解、3例完全缓解伴血液学不完全恢复。
  • 缓解者中90%达到MRD阴性(<0.1%),84%(n=16)成功桥接造血干细胞移植。

核心结论

  • 该联合方案在儿童R/R AML中耐受良好、具有生物学活性且有效,尤其在携带表观遗传学改变的患者中。

研究设计与样本

  • 1期试验含剂量扩展队列,研究地西他滨与伏立诺他联合FLAG方案治疗儿童R/R AML(NCT02412475)。
  • 37例患者入组,入组时中位年龄8.4岁(范围1-20岁)。

主要发现

  • 入组患者中未观察到剂量限制性毒性,包括2例唐氏综合征患者。
  • 地西他滨联合伏立诺他及FLAG的推荐2期剂量为10 mg/m2。
  • 35例可评估患者总缓解率为54%,包括16例完全缓解(CR)和3例完全缓解伴血液学不完全恢复(CRi)。
  • 缓解者中90%通过中心实验室流式细胞术达到MRD阴性(<0.1%),84%(n=16)成功进行造血干细胞移植。
  • MRD阴性患者2年总生存率为75.6%[95%CI: 47.3%, 90.1%],残留病患者为17.9%[95%CI: 4.4%, 38.8%](p < .001)。

关键数值与推荐

  • 地西他滨联合伏立诺他及FLAG的推荐2期剂量为10 mg/m2。
  • 35例可评估患者总缓解率为54%(16例CR和3例CRi)。
  • 缓解者中90%达到MRD阴性(<0.1%),84%(n=16)成功进行造血干细胞移植。
  • MRD阴性患者2年总生存率为75.6%[95%CI: 47.3%, 90.1%],残留病患者为17.9%[95%CI: 4.4%, 38.8%](p < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. Epigenetic changes can result in gene expression alterations which are thought to contribute to both leukemogenesis and chemotherapy resistance. We report results from a phase I trial with a dose expansion cohort investigating decitabine and vorinostat in combination with fludarabine, cytarabine, and G-CSF (FLAG) in pediatric patients with R/R AML [NCT02412475]. Thirty-seven patients enrolled with a median age at enrollment of 8.4 (range, 1-20) years. There were no dose limiting toxicities among the enrolled patients, including two patients with Down syndrome. The recommended phase 2 dose of decitabine in combination with vorinostat and FLAG was 10 mg/m2 . The expanded cohort design allowed for an efficacy evaluation and the overall response rate among 35 evaluable patients was 54% (16 complete response (CR) and 3 complete response with incomplete hematologic recovery (CRi)). Ninety percent of responders achieved minimal residual disease (MRD) negativity (<0.1%) by centralized flow cytometry and 84% (n = 16) successfully proceeded to hematopoietic stem cell transplant. Two-year overall survival was 75.6% [95%CI: 47.3%, 90.1%] for MRD-negative patients vs. 17.9% [95%CI: 4.4%, 38.8%] for those with residual disease (p < .001). Twelve subjects (34%) had known epigenetic alterations with 8 (67%) achieving a CR, 7 (88%) of whom were MRD negative. Correlative pharmacodynamics demonstrated the biologic activity of decitabine and vorinostat and identified specific gene enrichment signatures in nonresponding patients. Overall, this therapy was well-tolerated, biologically active, and effective in pediatric patients with R/R AML, particularly those with epigenetic alterations.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pommert L, Schafer ES, Malvar J, et al. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022. PMID: 35180323. doi:10.1002/ajh.26510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。